CATEGORIES: Research

HNF-WVU-NIOSH Study update:

by | May 9, 2013 | 0 comments

HNF_TRIADlogo-croppedWe are pleased to update our readers on the progress of the WVU-NIOSH study, “A Bi-Directional Translational Model of Exercise Training in the Treatment of Charcot-Marie-Tooth Disease”, funded by HNF. The breeding pair of transgenic CMT1A rats received from the Max Planck Institute for Experimental Medicine successfully passed through quarantine and recently produced a litter of 16 pups. The researchers plan on selecting two more breeding pairs from this group to continue the successful colonization of these animals. The remaining animals will be tested to confirm the presence of CMT1A and to characterize their muscles and nerves for future comparison to animals exposed to exercise training, and, eventually, animals receiving neurotrophic drugs/gene therapies alone or combined with exercise. The exercise testing phase is on schedule to begin late summer 2013. Once the scientists determine which exercise program produces the greatest benefit in the CMT animals, this HNF-sponsored research will progress to determine if the combination of drugs/gene therapies and exercise is more effective than either drugs/gene therapies or exercise alone.

Did you know? HNF, through the fundraising efforts of Team CMT and the generosity of HNF supporters, is responsible for the first successful colonization of transgenic CMT animals in the United States

Learn more on this topic

Related Blog Posts

Quality of Life and CMT Research

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

New Study on CMT Type 2B

If we are to learn more about CMT and the effectiveness of rehabilitation it is worth asking the patient and their caregiver. A recent Italian study by Padua et al recently described a survey of CMT patients and caregivers and their perspectives and perceptions of rehabilitation efficacy and needs.

Allison Moore is going to be published!

HNF’s CSO (Chief Scientific Officer), Sean Ekins wrote a blog about his work with Allison Moore and her two “fighter Mom” friends Lori Sames and Jill Wood. He named his blog: “Rare disease heroes – Extraordinary collaborators we should be listening too.” Sean helped my friends and I write a paper called: “Multifaceted roles of ultra rare and rare disease patients/parents in drug discovery.” YES, Allison Moore is going to be published! It will be in Drug Discovery Today, soon. The link to the reprint is below.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news